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SULFORAPHANE TREATMENT OF CHILDREN WITH AUTISM SPECTRUM DISORDER – A 
PROGRESS REPORT 
 
Eileen Diggins, BA, Andrew Zimmerman, MD, Kanwaljit Singh, MD, Susan Connors, MD 
Division of Neurology, Department of Pediatrics, University of Massachusetts Medical School 
 
This ongoing clinical trial in autism spectrum disorder (ASD) tests a nontoxic approach to 
therapy of ASD. 
 
Background: Direct treatment of underlying mechanisms in ASD is limited. Cellular dysfunction 
in ASD may involve a number of related metabolic pathways. The “fever effect” in ASD, in which 
febrile illness dramatically but temporarily ameliorates disordered behavior, offers a clinical clue. 
Fever stimulates heat shock proteins (HSP) and cellular stress responses that may ultimately 
lead to improved synaptic function and increased long-range connectivity. The expression of 
gene transcription by NFE2L2 (Nrf2), which is reduced in ASD, may also increase during fever. 
Sulforaphane (SF), an isothiocyanate obtained from 3-day-old broccoli sprouts, induces HSP 
and Nrf2 as well as “cell-protective” responses. SF has several possible modes of action that 
may benefit ASD through common cellular mechanisms underlying heterogeneous phenotypes. 
SF crosses the blood-brain barrier and is bioavailable orally. 
 
Preliminary data: In a randomized, double-blind, placebo-controlled pilot trial in 44 male 
adolescents and adults (13-30 years), results showed SF was well tolerated without significant 
side effects. On average, participants on SF (particularly those with a history of fever effect) 
showed significantly more improvements in ASD symptoms – including social interaction, 
aberrant/abnormal behavior, repetitive/stereotypical behavior, and verbal communication – than 
placebo participants. 
 
Current study: Our randomized, double-blind, placebo-controlled phase-2 clinical trial at 
UMass has three aims: To determine: (1) if orally administered SF has measurable effects in 
children (ages 3-12 years) with ASD; (2) if treatment with sulforaphane is safe and well 
tolerated; (3) To elucidate cellular biomarkers that support the mechanisms of action of SF in 
ASD. We hypothesize that positive effects of SF will be more marked and lasting in the 
developing brain. To date, 7 participants have completed the trial, and 22 are actively enrolled. 
Recruitment is ongoing, with a target sample size of 50. 
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